A5227 (Females only)

The Effect of Prior Short Course Combination Antiretroviral Therapy Administered for the Prevention of Mother-to-Child Transmission (pMTCT) of HIV-1 on Subsequent Treatment Efficacy in Treatment -"Nearly Naïve" Participants

Who Can Enroll: Women who were previously treated with short-term HIV therapy to prevent MTCT during pregnancy. Now require long term HIV tx. VL>500 No HAART within 6 months of study entry.

Study Therapy: Efavirenz plus Truvada. All meds provided by study.

Study RN: Please contact Karen Savage at 205-975-7925.

 

A5257

A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naïve HIV-1-Infected Volunteers.

Who Can Enroll: ARV treatment naïve requiring therapy. VL >1000 Any CD4.

Study Therapy: Truvada plus either Raltegravir, ATZ/r or DRZ/r (all meds but ritonovir provided by study with co-pay reimbursed).

Study RN: Please contact Karen Savage at 205-975-7925.

 

A5262

A Pilot Efficacy and Safety Trial of Raltegravir Plus Darunavir/r for Treatment-Naïve HIV-1 Infected Subjects.

Who Can Enroll: HIV Treatment Naïve Renal Dysfunction OK (Not HD or PD). VL >/= 5000 Any CD4.

Study Therapy: Raltegravir plus Darunavir/r.

Study RN: Please contact Karen Savage at 205-975-792.

 

Merck Acute Infection

A Randomized Pilot Study of Raltegravir/Tenofovir/Emtricitibine versus Efavirenz/Tenofovir/Emtricibine for Adults with Acute HIV-1 Infection: Exploring the Role of Integrase Inhibition in Early HIV Pathogenesis.

Who Can Enroll: Acute or Early HIV Infection. VL>5000 Any CD4.

Study Therapy: Raltegravir vs Sustiva in combination with Truvada (Raltegravir supplied by study).

Study RN: Please contact Kerry Upton at 205-975-9128.